AU757104B2 - Compositions and methods for inhibiting bone resorption - Google Patents

Compositions and methods for inhibiting bone resorption Download PDF

Info

Publication number
AU757104B2
AU757104B2 AU47025/99A AU4702599A AU757104B2 AU 757104 B2 AU757104 B2 AU 757104B2 AU 47025/99 A AU47025/99 A AU 47025/99A AU 4702599 A AU4702599 A AU 4702599A AU 757104 B2 AU757104 B2 AU 757104B2
Authority
AU
Australia
Prior art keywords
geranylgeranyl
nitrogen
isoprenoid compound
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47025/99A
Other languages
English (en)
Other versions
AU4702599A (en
Inventor
Alfred A. Reszka
Edward M. Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817172.1A external-priority patent/GB9817172D0/en
Priority claimed from GBGB9822330.8A external-priority patent/GB9822330D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU4702599A publication Critical patent/AU4702599A/en
Application granted granted Critical
Publication of AU757104B2 publication Critical patent/AU757104B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU47025/99A 1998-06-24 1999-06-21 Compositions and methods for inhibiting bone resorption Ceased AU757104B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US9040198P 1998-06-24 1998-06-24
US60/090401 1998-06-24
US9291998P 1998-07-15 1998-07-15
US60/092919 1998-07-15
GBGB9817172.1A GB9817172D0 (en) 1998-08-06 1998-08-06 Compositions and methods for inhibiting bone resorption
GB9817172 1998-08-06
GB9822330 1998-10-13
GBGB9822330.8A GB9822330D0 (en) 1998-10-13 1998-10-13 Compositions and methods for inhibiting bone resorption
PCT/US1999/013967 WO1999067809A1 (en) 1998-06-24 1999-06-21 Compositions and methods for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
AU4702599A AU4702599A (en) 2000-01-10
AU757104B2 true AU757104B2 (en) 2003-01-30

Family

ID=27451815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47025/99A Ceased AU757104B2 (en) 1998-06-24 1999-06-21 Compositions and methods for inhibiting bone resorption

Country Status (6)

Country Link
US (2) US6432931B1 (https=)
EP (1) EP1088333A4 (https=)
JP (1) JP2002519305A (https=)
AU (1) AU757104B2 (https=)
CA (1) CA2336201A1 (https=)
WO (1) WO1999067809A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7715300A (en) * 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
US20040014812A1 (en) * 2000-11-08 2004-01-22 Santen Pharmaceutical Co. Ltd Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient
EP1380293A4 (en) * 2001-03-30 2009-03-18 Nisshin Oillio Group Ltd MEANS TO IMPROVE BONE MATERIAL CHANGE
CA2465854A1 (en) * 2001-11-08 2003-09-04 Merck & Co., Inc. Compounds useful in the treatment of anthrax
RU2294203C2 (ru) * 2001-12-21 2007-02-27 Дзе Проктер Энд Гэмбл Компани Способ лечения костных нарушений
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
KR100897837B1 (ko) * 2001-12-24 2009-05-15 테바 파마슈티컬 인더스트리즈 리미티드 분말 또는 과립 물질의 압착된 환상체 내에 싸인 활성성분의 코어 정제를 갖는 제형과, 이의 제조 방법 및 툴링
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
HRP20041013B1 (hr) * 2002-12-20 2013-10-25 F. Hoffmann - La Roche Ag Formulacija visoke doze ibandronata
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
JP4738007B2 (ja) * 2005-02-04 2011-08-03 久光製薬株式会社 骨粗鬆症治療用外用剤
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
US7704656B2 (en) * 2005-03-23 2010-04-27 Xerox Corporation Photoconductive imaging member
ES2323728T3 (es) * 2005-12-27 2009-07-23 Ipca Laboratories Limited Proceso mejorado para la fabricacion de 4-amino-hidroxibutilideno-1,1-bisfosfonico y sus sales.
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20080164004A1 (en) * 2007-01-08 2008-07-10 Anastasia Kolesnichenko Method and system of electromagnetic stirring for continuous casting of medium and high carbon steels
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
AU2012319143A1 (en) * 2011-10-04 2014-04-17 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone derivatives
US20130085283A1 (en) * 2011-10-04 2013-04-04 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone derivatives
WO2013130654A1 (en) * 2012-02-29 2013-09-06 Coyote Pharmaceuticals, Inc. Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
WO2014055440A1 (en) * 2012-10-01 2014-04-10 Coyote Pharmaceuticals, Inc. Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
WO2014101051A1 (en) 2012-12-27 2014-07-03 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
GB2524207B (en) 2012-12-27 2020-07-29 Kimberly Clark Co Water soluble essential oils and their use
WO2014151719A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
WO2014151697A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Therapeutic uses for geranylgeranyl acetone and derivatives thereof
KR102363895B1 (ko) * 2020-03-02 2022-02-17 영남대학교 산학협력단 염증 질환 또는 면역 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB938712A (en) * 1961-05-24 1963-10-02 Angeli Inst Spa Farnesyl acetic esters
JPS5612114B2 (https=) 1974-06-07 1981-03-18
JPS5573642A (en) * 1978-11-28 1980-06-03 Kuraray Co Ltd Farnesyl-acetic ester derivative
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS57106644A (en) * 1980-12-20 1982-07-02 Kotobuki Seiyaku Kk Farnesence derivative, mucosa stabilizer comprising it as active ingredient, and its preparation
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US4933165A (en) 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
WO1991005754A2 (fr) 1989-10-13 1991-05-02 Medafor Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant
US5101068A (en) 1990-02-16 1992-03-31 Prototek Inc. Magnesium fluoromalonates
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
CA2036962C (en) 1990-02-26 1998-09-15 Ann E. Decamp Process for the desilylation of a 4-silyloxy-tetrahydro-pyran-2-one
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
EP0522576A3 (en) 1991-07-12 1993-07-14 Hoechst Aktiengesellschaft Aminoethane-1,1-bisphosphonic acids and aminoethane-1,1-alkylphospinic/phosphonic acids, process of their preparation and their use
US5128328A (en) 1991-10-25 1992-07-07 American Home Products Corporation Heterocyclic bisphosphonic acid derivatives
AU3666893A (en) 1992-02-21 1993-09-13 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5985838A (en) 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
TW257765B (https=) 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5712261A (en) * 1993-10-04 1998-01-27 Magnin; David R. Method for preventing or treating hypertriglyceridemia
JP3674956B2 (ja) * 1994-01-28 2005-07-27 エーザイ株式会社 抗骨粗鬆症剤
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5574025A (en) 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
IL113246A (en) 1995-04-04 2004-08-31 Yissum Res Dev Co Bisphosphonates and pharmaceutical compositions containing them
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5618964A (en) 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
JPH0930977A (ja) * 1995-07-20 1997-02-04 Tsuneo Nanba 升麻抽出物を含有する骨疾患治療剤
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US5817816A (en) * 1996-06-20 1998-10-06 Meiji Seika Kaisha, Ltd. Sesquiterpene derivatives having progesterone receptor binding inhibitory activity
US6083979A (en) 1996-10-09 2000-07-04 University Of Pittsburgh Geranylgeraniol/lovastatin: a novel approach to blocking cancer transformation without cytotoxicity
US5777326A (en) * 1996-11-15 1998-07-07 Sensor Corporation Multi-anode time to digital converter
US5763646A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
JPH11130670A (ja) 1997-10-27 1999-05-18 Oyo Seikagaku Kenkyusho 骨粗鬆症治療剤

Also Published As

Publication number Publication date
AU4702599A (en) 2000-01-10
WO1999067809A9 (en) 2001-03-22
EP1088333A4 (en) 2005-08-10
US20020082244A1 (en) 2002-06-27
CA2336201A1 (en) 1999-12-29
US6699850B2 (en) 2004-03-02
JP2002519305A (ja) 2002-07-02
US6432931B1 (en) 2002-08-13
WO1999067809A1 (en) 1999-12-29
EP1088333A1 (en) 2001-04-04

Similar Documents

Publication Publication Date Title
AU757104B2 (en) Compositions and methods for inhibiting bone resorption
NZ530113A (en) Method for inhibiting bone resorption in a unit dosage form
CA2337381A1 (en) Compositions and methods for treating osteoporosis
CA2294595C (en) Inhibiting bone resorption
AU761138B2 (en) Compositions and methods for inhibiting bone resorption
US20020004218A1 (en) Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
AU775239B2 (en) Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
US20030078211A1 (en) Compositions and methods for inhibiting bone resorption
US20040180862A1 (en) Compositions and methods for inhibiting bone resorption
AU2001252997A1 (en) Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
AU2002303925A1 (en) Compositions and methods for inhibiting bone resorption
CA2349733A1 (en) Inhibition bone resorption
MXPA00000789A (en) Method for inhibiting bone resorption
CZ2000250A3 (cs) Farmaceutický prostředek

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)